Zobrazeno 1 - 2
of 2
pro vyhledávání: '"MESH: Osteosarcoma/drug therapy"'
Autor:
Roberta Mazzone, Piero Picci, Katia Scotlandi, Michela Pasello, Patrizia Nanni, Giordano Nicoletti, Maria Cristina Manara, Antonello Mai, Clara Guerzoni, Camilla Cristalli, Pier Luigi Lollini, Lorena Landuzzi, Sergio Valente, Giulia Stazi, Paola B. Arimondo, Clemens Zwergel
Publikováno v:
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics, American Association for Cancer Research, 2018, 17 (9), pp.1881-1892. ⟨10.1158/1535-7163.MCT-17-0818⟩
Molecular Cancer Therapeutics, American Association for Cancer Research, 2018, 17 (9), pp.1881-1892. ⟨10.1158/1535-7163.MCT-17-0818⟩
The identification of new therapeutic strategies against osteosarcoma, the most common primary bone tumor, continues to be a primary goal to improve the outcomes of patients refractory to conventional chemotherapy. Osteosarcoma originates from the tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e55d5482d55dc2ed43ad6818ec4cbf60
https://hal.archives-ouvertes.fr/hal-02383680
https://hal.archives-ouvertes.fr/hal-02383680
Autor:
Stephen P. Jackson, Mareike Herzog, Alejandra Bruna, Luca Pellegrini, Violeta Serra, Mark J. O'Connor, Zhongwu Lai, Chloé Lescale, Jacqueline J.L. Jacobs, Fengtang Yang, Jonathan Lam, Matylda Sczaniecka-Clift, Abigail Shea, Carlos Caldas, Matthias Ostermaier, Gabriel Balmus, Julia Coates, Wenming Wei, Inge de Krijger, Yaron Galanty, Mukerrem Demir, Ludovic Deriano, Petra Beli, Domenic Pilger, Harveer Dev, Rimma Belotserkovskaya, Alistair Martin, Beiyuan Fu, Ting-Wei Will Chiang, Qian Wu
Publikováno v:
Nature Cell Biology
Nature Cell Biology, 2018, 20 (8), pp.954-965. ⟨10.1038/s41556-018-0140-1⟩
Nature cell biology
Nature Cell Biology, Nature Publishing Group, 2018, 20 (8), pp.954-965. ⟨10.1038/s41556-018-0140-1⟩
Nature Cell Biology, 2018, 20 (8), pp.954-965. ⟨10.1038/s41556-018-0140-1⟩
Nature cell biology
Nature Cell Biology, Nature Publishing Group, 2018, 20 (8), pp.954-965. ⟨10.1038/s41556-018-0140-1⟩
International audience; BRCA1 deficiencies cause breast, ovarian, prostate and other cancers, and render tumours hypersensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. To understand the resistance mechanisms, we conducted whole-genome CRISP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94c03882fb1aad0056e71d15c34e8ed4
https://www.repository.cam.ac.uk/handle/1810/282947
https://www.repository.cam.ac.uk/handle/1810/282947